Graft Polymer (UK) - Directorate Change

Solvonis Therapeutics

15/07/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240715:nRSO2963Wa&default-theme=true

RNS Number : 2963W  Graft Polymer (UK) PLC  15 July 2024

15 July 2024

Graft Polymer (UK) Plc

("Graft Polymer" or the "Company")

 

Director resignation and launch of new corporate website and social media
profiles

Graft Polymer (UK) Plc (LON: GPL), an innovative biopolymer drug delivery
systems development company, announces the resignation of Mr. Pavel Kobzev
from its board of directors with immediate effect. This follows the Company's
recent divestiture of its industrial plastics business unit, Graft Polymer
D.O.O., announced on 3 May 2024, and the successful completion of its recent
fundraise, details of which were announced on 3 July 2024.

Additionally, the Company is pleased to announce the launch of its new
corporate website and updated LinkedIn and X (formerly Twitter) profiles.
These platforms are designed to reflect the Company's strategic focus on
supporting biopharmaceutical companies to enhance the bioavailability,
pharmacokinetics, and stability of their therapeutics.

Visit us online:

www.graftpolymer.co.uk (http://www.graftpolymer.co.uk)

LinkedIn (http://www.linkedin.com/company/graft-polymer-uk-plc)

X (formerly Twitter) (https://x.com/GraftPolymerPlc)

 

Enquiries

Graft Polymer (UK) Plc

Anthony Tennyson, CEO and Executive Director, Email:
anthonytennyson@graftpolymer.co.uk

Yifat Steuer, CFO and Executive Director, Email: yifat@graftpolymer.co.uk

 

Allenby Capital (Broker)

Nick Naylor / Liz Kirchner / James Reeve (Corporate Finance)

Guy McDougall (Sales)

+44 (0) 20 3328 5656

 

About Graft Polymer (UK) Plc

 

Graft Polymer (UK) Plc (LON:GPL) is an innovative developer of biopolymer drug
delivery systems dedicated to assisting biopharmaceutical companies in
enhancing the effectiveness of their therapeutics. Our proprietary patented
platform, a bioabsorbable self-nanoemulsifying drug delivery system (SNEDDS),
represents a cutting-edge solution in drug delivery technology. By integrating
active pharmaceutical ingredients (APIs) into our novel, patented delivery
systems, we enable clients to improve the bioavailability, pharmacokinetics,
and stability of their therapeutics.

www.graftpolymer.co.uk (http://www.graftpolymer.co.uk) | LinkedIn
(http://www.linkedin.com/company/graft-polymer-uk-plc) | X (formerly Twitter)
(https://x.com/GraftPolymerPlc)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAKZGMNKZRGDZM